How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biological Heart Valves Market
- By Valve Type: Porcine Valve, Bovine Pericardial Valve, Equine Valve, Human (Homograft) Valve
- By Valve Position: Aortic Valve, Mitral Valve, Pulmonary Valve, Tricuspid Valve
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Valve Design: Stented Valve, Stentless Valve, Sutureless Valve
- By Application: Surgical Valve Replacement, Transcatheter Valve Replacement
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Porcine Valve leads By Valve Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Biological Heart Valves Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Valve Type 4
Valve Position 4
Patient Age Group 3
Valve Design 3
Application 2
Companies profiled
Edwards Lifesciences Corporation
Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
CryoLife Inc.
Terumo Corporation
Sorin Group (now part of LivaNova)
Corcym S.p.A.
Shanghai MicroPort Medical (Group) Co. Ltd.
JenaValve Technology Inc.
Braile Biomédica
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Edwards Lifesciences Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →CryoLife Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sorin Group (now part of LivaNova)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Corcym S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shanghai MicroPort Medical (Group) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →JenaValve Technology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Braile Biomédica
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Meril Life Sciences Pvt. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →NVT AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →ValveXchange
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$2,934M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Porcine Valve65.0
- Bovine Pericardial Valve13.8
- Equine Valve12.1
- Human (Homograft) Valve9.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$410.4M → $990.8M · 11.6%
Europe$286.0M → $725.8M · 12.3%
Asia Pacific$261.1M → $608.8M · 11.2%
Latin America$161.7M → $366.2M · 10.8%
Middle East and Africa$124.4M → $304.4M · 11.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.272026
11.282027
11.312028
11.312029
11.322030
11.332031
11.362032
11.372033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Edwards Lifesciences Corporation19.6
- Medtronic plc17.0
- Abbott Laboratories11.4
- Boston Scientific Corporation7.6
- LivaNova PLC9.3
- CryoLife Inc.7.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Valve Type23.2%
Valve Position19.6%
Patient Age Group15.9%
Valve Design18.2%
Application23.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe24.2
- Asia Pacific20.3
- Latin America12.2
- Middle East and Africa10.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | 74 | 85 | 87 | 98 | 92 | 79 | 86 |
| Medtronic plc | 91 | 90 | 78 | 81 | 88 | 78 | 84 |
| Abbott Laboratories | 72 | 83 | 68 | 76 | 86 | 63 | 75 |
| Boston Scientific Corporation | 59 | 57 | 79 | 61 | 70 | 81 | 68 |
| LivaNova PLC | 61 | 62 | 65 | 67 | 73 | 55 | 64 |
| CryoLife Inc. | 52 | 63 | 47 | 51 | 66 | 51 | 55 |
| Terumo Corporation | 50 | 53 | 50 | 46 | 53 | 44 | 49 |
| Sorin Group (now part of LivaNova) | 56 | 48 | 57 | 38 | 45 | 42 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Edwards Lifesciences Corporation
- Medtronic plc
- Abbott Laboratories
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Medtronic plc | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Boston Scientific Corporation | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| LivaNova PLC | − | − | ◐ | − | ◐ | ◐ |
| CryoLife Inc. | − | ◐ | ◐ | ◐ | − | − |
| Terumo Corporation | − | − | − | ◐ | − | − |
| Sorin Group (now part of LivaNova) | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Edwards Lifesciences Corporation86
2Medtronic plc84
3Abbott Laboratories75
4Boston Scientific Corporation68
5LivaNova PLC64
6CryoLife Inc.55
7Terumo Corporation49
8Sorin Group (now part of LivaNova)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Edwards Lifesciences CorporationMedtronic plc
Challenger2
Strong scale, closing on the leaders.
Abbott LaboratoriesBoston Scientific Corporation
Contender1
Focused players with pockets of strength.
LivaNova PLC
Niche3
Specialists in a single segment or region.
CryoLife Inc.Terumo CorporationSorin Group (now part of LivaNova)
Go-to-market strategy
Land Valve Type in North America, then scale across Biological Heart Valves Market — a $539M beachhead inside a $7.77B market.
Beachhead (SOM)$539Mobtainable near-term
Serviceable (SAM)$3.05Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Porcine Valve
Best fit — highest urgency & budget in Valve Type.
Economic buyer75 fit
Bovine Pericardial Valve
Strong fit — clear ROI and a fast path to value.
End user67 fit
Equine Valve
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Valve Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Valve Position & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel25%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Valve Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biological Heart Valves Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified23%
Evaluation13%
Closed-won5%
$14.4KCAC
$59KLTV
4.1:1LTV : CAC
< 4 moCAC payback
Investment thesis
Biological Heart Valves Market is a durable-growth opportunity — $9.94B by 2033, compounding at 8.6%.
TAM · 2025$5.12Btoday
TAM · 2033$9.94Bforecast
CAGR8.6%2027–2033
Cumulative$65.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.94BTotal addressable market
SAM$3.77BServiceable available market
SOM$641MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.6% CAGR
Demand compounds through 2033, outpacing GDP across Valve Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Valve Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.94BLarge & growingTAM by 2033 at 8.6% CAGR
$3.77BServiceable nowreachable with today’s model
$641MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.75BBear5.6% CAGR
$9.94BBase8.6% CAGR
$12.7BBull11.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Valve Position optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biological Heart Valves Market — a $6.49B market by 2033. Plan: grow share from 9.1% to 14.9%.
Market size · 2033$6.49Btotal addressable
Market CAGR5.2%2027–2033
Target share14.9%from 9.1% today
Revenue ambition$967Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.9% | On track |
| Revenue | $637M | $967M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 37.5% | 41.5% | On track |
| Customer retention | 88.6% | 95.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Valve Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Valve Position capability
A defensible second engine — invest in Valve Position to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Valve Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Valve Position
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $117M capacity & capability investment
- Greenlight bolt-on M&A in Valve Position
- Authorise North America expansion plan
- Fund R&D program for Valve Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Biological Heart Valves Market conversation — a $8.45B market you can size, segment and defend in minutes.
Market size · 2033$8.45Btotal opportunity
Growth6.2%CAGR to 2033
Addressable buyers1,510+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Valve Type
Goal Grow share in Valve Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$40K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Edwards Lifesciences CorporationMedtronic plcAbbott LaboratoriesBoston Scientific CorporationLivaNova PLCCryoLife Inc.Terumo CorporationSorin Group (now part of LivaNova)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biological Heart Valves Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biological Heart Valves Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biological Ice Bag Market
Market size, share, segmentation and regional forecast.
$477M market · 2025 base year
View reportBiological Indicator Incubator Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBiological Indicator Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportBiological Integrated Circuit Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBiological Microscope Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBiological Naphtha Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBiological Nerve Chip Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBiological Oxygen Demand (Bod) Analyzers Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBiological Particles Machine Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportBiological Pesticide(Biopestcides) Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBiological Recognition Systems Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBiological Safety Cabinet [Biosafety Cabinet] Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.